Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by ScienceFirston Mar 07, 2022 8:17am
214 Views
Post# 34489464

2 points to monitor in the next round of data

2 points to monitor in the next round of dataI don't expect many new patients treated since the Nov. 29 report, given the surge of Omicron early December to mid-January that might have slowed the recruitment/enrollment/treatment.  
 
From this Master patient data tracker graciously provided by Djdawg on Dec. 8., my focus in the next round of data will rather be:
 
1) to see if the 90-days pending status of p#20-26 have all turned CR
 
2) if the « 70% (7/10) of CR at 90-days still CR at 180-days) » has turned « 70% (7/10) of CR at 90-days still CR at 270-days) »

If we hit good on these 2 points, then I think the odds of getting the next standard of care are becoming stronger and stronger statistically.  We would then have a very stable and predictable treatment.
 

from this Master patient data tracker graciuousy provided by djdawg on Dec. 8.
<< Previous
Bullboard Posts
Next >>